Digest Network Come funziona
Network
/
Società
Br
Non verificato

BridgeBio Oncology Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

8 comunicati stampa

Guarda tutti i comunicati
01/04/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors
Fonte
BridgeBio Oncology Therapeutics
Emittente
Business Wire
1.00
0
28/02/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato del lavoro
Titoli e azioni
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines
Fonte
BridgeBio Oncology Therapeutics
Emittente
Business Wire
1.00
0
09/01/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metastatic Non-Small Cell Lung Cancer
Fonte
BridgeBio Oncology Therapeutics
Emittente
Business Wire
1.00
0
23/12/2024
Eventi
Fiere
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Fonte
BridgeBio Oncology Therapeutics
Emittente
Business Wire
1.00
0
09/12/2024
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provide Therapeutic Benefit in KRASG12C Mutant Tumors
Fonte
BridgeBio Oncology Therapeutics
Emittente
Business Wire
1.00
0
18/11/2024
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato del lavoro
BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director
Fonte
BridgeBio Oncology Therapeutics
Emittente
Business Wire
1.00
0
30/10/2024
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors
Fonte
BridgeBio Oncology Therapeutics
Emittente
Business Wire
1.00
0
09/09/2024
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer
Fonte
BridgeBio Oncology Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0